New combo therapy shows promise for tough lung cancer

NCT ID NCT04745689

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy. The goal is to see if this approach improves how long people live without their cancer getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

Grand Rapids, Michigan, 49503, United States
Research Site

Bydgoszcz, 85-796, Poland
Research Site

Olsztyn, 10-357, Poland
Research Site

Poznan, 60-693, Poland
Research Site

Cheongju-si, 28644, South Korea
Research Site

Jinju, 52727, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Seville, 41071, Spain
Research Site

Valencia, 46015, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.